CagriSema Shows Strong Dose-Specific Benefits for Type 2 Diabetes in Landmark Meta-Analysis
A new meta-analysis of six randomized controlled trials shows CagriSema significantly lowers HbA1c, body weight, and blood pressure in type ...
A new meta-analysis of six randomized controlled trials shows CagriSema significantly lowers HbA1c, body weight, and blood pressure in type ...
A new review in Diabetes Therapy finds that three amylin-based agonists—zenagamtide, eloralintide and CagriSema—deliver unprecedented weight loss and, in some ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine